Literature DB >> 33602258

Challenges and opportunities for ovarian cancer management in the epidemic of Covid-19: lessons learned from Wuhan, China.

Zhilan Chen1, Chun Zhang1, Jiu Yin1, Xin Xin1, Hemei Li1, Yapei Wang1, Benjamin K Tsang2, Qinghua Zhang3.   

Abstract

China and the rest of the world are experiencing an outbreak of the 2019 novel coronavirus disease (COVID-19). Patients with cancer are more susceptible to viral infection and are more likely to develop severe complications, as compared to healthy individuals. The growing spread of COVID-19 presents challenges for the clinical care of patients with gynecological malignancies. Ovarian debulking surgery combined with the frequent need for chemotherapy is most likely why ovarian cancer was rated as the gynecologic cancer most affected by COVID-19. Therefore, ovarian cancer presents a particular challenging task. Concerning the ovarian cancer studies with confirmed COVID-19 reported from large-scale general hospitals in Wuhan, we hold that the treatment plan was adjusted appropriately and an individualized remedy was implemented. The recommendations discussed here were developed mainly based on the experience from Wuhan. We advise that the management strategy for ovarian cancer patients should be adjusted in the light of the local epidemic situation and formulated according to the pathological type, tumor stage and the current treatment phase. Online medical service is an effective and convenient communication platform during the pandemic.

Entities:  

Keywords:  Covid-19; Management; Ovarian cancer; Pandemic

Year:  2021        PMID: 33602258      PMCID: PMC7891806          DOI: 10.1186/s13048-021-00784-2

Source DB:  PubMed          Journal:  J Ovarian Res        ISSN: 1757-2215            Impact factor:   4.234


  42 in total

1.  NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019.

Authors:  Deborah K Armstrong; Ronald D Alvarez; Jamie N Bakkum-Gamez; Lisa Barroilhet; Kian Behbakht; Andrew Berchuck; Jonathan S Berek; Lee-May Chen; Mihaela Cristea; Marie DeRosa; Adam C ElNaggar; David M Gershenson; Heidi J Gray; Ardeshir Hakam; Angela Jain; Carolyn Johnston; Charles A Leath; Joyce Liu; Haider Mahdi; Daniela Matei; Michael McHale; Karen McLean; David M O'Malley; Richard T Penson; Sanja Percac-Lima; Elena Ratner; Steven W Remmenga; Paul Sabbatini; Theresa L Werner; Emese Zsiros; Jennifer L Burns; Anita M Engh
Journal:  J Natl Compr Canc Netw       Date:  2019-08-01       Impact factor: 11.908

2.  [Management strategies for three patients with gynecological malignancies during the outbreak of COVID-19].

Authors:  J Zhang; P Peng; X Li; Y F Zha; Y Xiang; G N Zhang; Y Zhang
Journal:  Zhonghua Fu Chan Ke Za Zhi       Date:  2020-04-25

3.  Impact of the coronavirus disease 2019 pandemic on the quality of life for women with ovarian cancer.

Authors:  Melissa K Frey; Annie E Ellis; Kristen Zeligs; Eloise Chapman-Davis; Charlene Thomas; Paul J Christos; Valentin Kolev; Monica Prasad-Hayes; Samantha Cohen; Kevin Holcomb; Stephanie V Blank
Journal:  Am J Obstet Gynecol       Date:  2020-06-26       Impact factor: 8.661

Review 4.  Recommendations on management of gynecological malignancies during the COVID-19 pandemic: perspectives from Chinese gynecological oncologists.

Authors:  Yingmei Wang; Shiqian Zhang; Lihui Wei; Zhongqiu Lin; Xinyu Wang; Jianliu Wang; Keqin Hua; Manhua Cui; Jiandong Wang; Shixuan Wang; Wen Di; Yudong Wang; Ruifang An; Mingrong Xi; Ruixia Guo; Qi Zhou; Xing Xie; Fengxia Xue
Journal:  J Gynecol Oncol       Date:  2020-05-27       Impact factor: 4.401

5.  Management of ovarian cancer patients in affected areas during COVID-19 pandemic: Japan and Korea.

Authors:  Yusuke Kobayashi; Dong Hoon Suh; Daisuke Aoki; Jae Weon Kim
Journal:  J Gynecol Oncol       Date:  2020-05       Impact factor: 4.401

Review 6.  The experience on coronavirus disease 2019 and cancer from an oncology hub institution in Milan, Lombardy Region.

Authors:  Dario Trapani; Antonio Marra; Giuseppe Curigliano
Journal:  Eur J Cancer       Date:  2020-04-29       Impact factor: 9.162

7.  SARS-CoV-2 infection in cancer patients undergoing active treatment: analysis of clinical features and predictive factors for severe respiratory failure and death.

Authors:  Ramón Yarza; Mateo Bover; Diana Paredes; Flora López-López; Diego Jara-Casas; Alicia Castelo-Loureiro; Javier Baena; José María Mazarico; María Dolores Folgueira; María Ángeles Meléndez-Carmona; Alhena Reyes; Carlos Lumbreras; Luis Paz-Ares; Carmen Díaz-Pedroche; Carlos Gómez-Martín
Journal:  Eur J Cancer       Date:  2020-06-06       Impact factor: 9.162

8.  Perioperative SARS-CoV-2 infection among women undergoing major gynecologic cancer surgery in the COVID-19 era: A nationwide, cohort study from Turkey.

Authors:  Ali Ayhan; Murat Oz; Nazli Topfedaisi Ozkan; Koray Aslan; Müfide Iclal Altintas; Hüseyin Akilli; Erdal Demirtas; Osman Celik; Mustafa Mahir Ülgü; Suayip Birinci; Mehmet Mutlu Meydanli
Journal:  Gynecol Oncol       Date:  2020-11-17       Impact factor: 5.482

9.  Recommendations for the surgical management of gynecological cancers during the COVID-19 pandemic - FRANCOGYN group for the CNGOF.

Authors:  Cherif Akladios; Henri Azais; Marcos Ballester; Sofiane Bendifallah; Pierre-Adrien Bolze; Nicolas Bourdel; Alexandre Bricou; Geoffroy Canlorbe; Xavier Carcopino; Pauline Chauvet; Pierre Collinet; Charles Coutant; Yohann Dabi; Ludivine Dion; Tristan Gauthier; Olivier Graesslin; Cyrille Huchon; Martin Koskas; Frederic Kridelka; Vincent Lavoue; Lise Lecointre; Matthieu Mezzadri; Camille Mimoun; Lobna Ouldamer; Emilie Raimond; Cyril Touboul
Journal:  J Gynecol Obstet Hum Reprod       Date:  2020-04-01

10.  SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China.

Authors:  Jing Yu; Wen Ouyang; Melvin L K Chua; Conghua Xie
Journal:  JAMA Oncol       Date:  2020-07-01       Impact factor: 31.777

View more
  1 in total

Review 1.  A Clinical Diagnostic Value Analysis of Serum CA125, CA199, and HE4 in Women with Early Ovarian Cancer: Systematic Review and Meta-Analysis.

Authors:  Xiaolin Qing; Liting Liu; Xiguang Mao
Journal:  Comput Math Methods Med       Date:  2022-05-25       Impact factor: 2.809

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.